Literature DB >> 11508279

The accelerator hypothesis: weight gain as the missing link between Type I and Type II diabetes.

T J Wilkin1.   

Abstract

Blood glucose concentrations are controlled by a loop incorporating two components, the beta cells which secrete insulin and the insulin-sensitive tissues (liver, muscle, adipose) which respond to it. Loss of blood glucose control might result from failure of the beta cells to secrete insulin, resistance of the tissues to its action, or a combination of both. The distinctions between Type I (insulin-dependent) and Type II (non-insulin-dependent) diabetes mellitus are becoming increasingly blurred both clinically and aetiologically, where beta-cell insufficiency is the shared characteristic. The 'Accelerator Hypothesis' identifies three processes which variably accelerate the loss of beta cells through apoptosis: constitution, insulin resistance and autoimmunity. None of the accelerators leads to diabetes without excess weight gain, a trend which the 'Accelerator Hypothesis' deems central to the rising incidence of both types of diabetes in the industrially developed world. Weight gain causes an increase in insulin resistance, which results in the weakening of glucose control. The rising blood glucose (glucotoxicity) accelerates beta-cell apoptosis directly in all and, by inducing beta-cell immunogens, further accelerates it in a subset genetically predisposed to autoimmunity. Rather than overlap between two types of diabetes, the 'Accelerator Hypothesis' envisages overlay. Body mass is central to the development and rising incidence of all diabetes. Only tempo distinguishes the 'types'. The control of weight gain, and with it insulin resistance, could be the means of minimising both.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11508279     DOI: 10.1007/s001250100548

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  150 in total

1.  To: T.J. Wilkin (2001) The accelerator hypothesis: weight gain as the missing link between Type I and Type II diabetes. Diabetologia 44: 914-921.

Authors:  F K Gorus; I Weets; D G Pipeleers
Journal:  Diabetologia       Date:  2002-02       Impact factor: 10.122

2.  Continuing increase in incidence of childhood-onset type 1 diabetes in the Czech Republic 1990-2001.

Authors:  Ondrej Cinek; Zdenek Sumnik; Jan Vavrinec
Journal:  Eur J Pediatr       Date:  2003-04-18       Impact factor: 3.183

3.  β-cell autoimmunity in overweight non-diabetic youth: any implications?

Authors:  Ingrid M Libman; E Barinas-Mitchell; S Marcovina; F Bacha; T Hannon; H Tfayli; S J Lee; S Bansal; R Robertson; S Arslanian
Journal:  Pediatr Diabetes       Date:  2010-09-07       Impact factor: 4.866

4.  Braking the accelerator hypothesis?

Authors:  J R Porter; T G Barrett
Journal:  Diabetologia       Date:  2003-12-10       Impact factor: 10.122

Review 5.  Environmental triggers and determinants of beta-cell autoimmunity and type 1 diabetes.

Authors:  Mikael Knip
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

Review 6.  Environmental triggers of type 1 diabetes.

Authors:  Mikael Knip; Olli Simell
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

Review 7.  Epidemiology of type 1 diabetes.

Authors:  David M Maahs; Nancy A West; Jean M Lawrence; Elizabeth J Mayer-Davis
Journal:  Endocrinol Metab Clin North Am       Date:  2010-09       Impact factor: 4.741

8.  Onset features and subsequent clinical evolution of childhood diabetes over several years.

Authors:  Rebecca B Lipton; Melinda L Drum; Kirstie K Danielson; Siri Aw Greeley; Graeme I Bell; William A Hagopian
Journal:  Pediatr Diabetes       Date:  2011-03-23       Impact factor: 4.866

9.  Spring harvest? Reflections on the rise of type 1 diabetes.

Authors:  E A M Gale
Journal:  Diabetologia       Date:  2005-12       Impact factor: 10.122

10.  Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets.

Authors:  Kathrin Maedler; Pavel Sergeev; Frédéric Ris; José Oberholzer; Helen I Joller-Jemelka; Giatgen A Spinas; Nurit Kaiser; Philippe A Halban; Marc Y Donath
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.